
Renuka P Limgala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/936786/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants. JIMD Reports, 2021, 59, 60-68.	1.5	5
2	Pregnancy Outcomes in Late Onset Pompe Disease. Life, 2020, 10, 194.	2.4	4
3	The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. International Journal of Molecular Sciences, 2020, 21, 7213.	4.1	1
4	Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease. Biomolecules, 2020, 10, 526.	4.0	9
5	Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. American Journal of Translational Research (discontinued), 2019, 11, 1683-1696.	0.0	3
6	Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease. Blood Cells, Molecules, and Diseases, 2018, 68, 81-85.	1.4	5
7	Gaucheromas: When macrophages promote tumor formation and dissemination. Blood Cells, Molecules, and Diseases, 2018, 68, 100-105.	1.4	25
8	Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE, 2016, 11, e0168135.	2.5	25
9	Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2016, 59, 8-15.	1.4	19
10	A Pilot Study of Omalizumab in Eosinophilic Esophagitis. PLoS ONE, 2015, 10, e0113483.	2.5	114
11	Diffuse Cutaneous Mastocytosis, Bullous Variant, Presenting in a Six-Month-Old Infant. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 341-342.	3.8	2
12	Efficient Procurement of Epithelial Stem Cells from Human Tissue Specimens Using a Rho-Associated Protein Kinase Inhibitor Y-27632. Tissue Engineering - Part A, 2010, 16, 1363-1368.	3.1	64
13	Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site. Archives of Virology, 2006, 151, 509-524.	2.1	19
14	A Peptide Derived from RNA Recognition Motif 2 of Human La Protein Binds to Hepatitis C Virus Internal Ribosome Entry Site, Prevents Ribosomal Assembly, and Inhibits Internal Initiation of Translation. Journal of Virology, 2005, 79, 9842-9853.	3.4	21
15	La Protein Binding at the GCAC Site Near the Initiator AUG Facilitates the Ribosomal Assembly on the Hepatitis C Virus RNA to Influence Internal Ribosome Entry Site-mediated Translation. Journal of Biological Chemistry, 2004, 279, 29879-29888.	3.4	48
16	Leader RNA of Rinderpest virus binds specifically with cellular La protein: a possible role in virus replication. Virus Research, 2004, 104, 101-109.	2.2	17
17	Hepatitis C Virus Internal Ribosome Entry Site-mediated Translation Is Stimulated by Specific Interaction of Independent Regions of Human La Autoantigen. Journal of Biological Chemistry, 2003, 278, 12231-12240.	3.4	71